Biopharmaceutical stocks are targeting Crohn’s Disease in developing drugs in 2022. Research finds that this is a $13.7 billion market ripe for sector stock catalysts such as profit and dividends. 

CATALYSTS BIOTECH INVESTORS SHOULD MONITOR

Here are catalysts for buying into biopharmaceutical stocks targeting the development of Crohn’s Disease drugs in 2022:

— The market for Crohn’s Disease drug treatment is $13.7 billion, research reports. The sector is growing an annual CAGR of greater than 7.6%.

— M&A activity has heightened among Crohn’s Disease biopharmaceutical stocks. This indicates profitability as larger drug companies acquire smaller ones operating clinical studies for Crohn candidate drugs in clinical tests possibly leading to commercialization. 

— Crohn’s Disease is an active marketplace, leading to becoming a global volume and profit marker. In the U.S. alone, there are greater than 825,000 cases.

— Clinical studies for inflammatory diseases like Crohn’s Disease are a smart sector investment. Stock purchases in biopharmaceuticals in this sector can pay off big as drug candidates are in R&D development.

— Ongoing research trials for inflammatory diseases are focused on developing commercialized drugs in the marketplace.

STAB RECEIVES APPROVAL TO COMMENCE CLINICAL TRIALS FOR CROHN’s

Place STAB stock on your watch list as it is now progressing with next-gen R&D on its proprietary platform. Its leading drug candidate may become standard care for the treatment of Crohn’s.

— Statera Biopharma, Inc. (NASDAQ: STAB) is advancing next-gen research activities based on proprietary compositions from its own STAT-200 platform. The result is that promising new compositions are being developed to treat a range of inflammatory diseases. These include clinical programs for Crohn’s disease.

The Company has received Central Institutional Board Review (IRB) to conduct a Phase 3 Clinical Trial for its STAT-201 in the treatment of pediatric Crohn’s disease. This is an inflammatory condition of the gastrointestinal tract.

Michael K. Handley, President, and CEO of the biopharmaceutical company,  says STAT-201 is STAB’s most advanced drug candidate and is at trial to prove it can restore intestinal barrier function. It would then become a standard of care in the treatment of Crohn’s.

BIOPHARMACEUTICAL SECTOR STOCKS WITH 2022 CATALYSTS 

—Arena (NASDAQ: ARNA) has agreed to be acquired by Pfizer (NYSE: PFE) as M&A intensifies in the Biopharmaceutical world. Its leading drug candidate is Etrasimod, which is now being tested for the treatment of Crohn’s Disease. 

It is an oral drug that partially and reverses lymphocyte levels at inflammation sites. It also maintains immune function. Pfizer sees it dovetailing with its own large anti-inflammatory drug portfolio. 

— Redhill Biopharma (NASDAQ: RDHL) is scheduled to post quarterly earnings tomorrow before the market opens for trading. The 50-day moving average for this stock is $2.32.

This is a company focused on developing gastrointestinal drugs and treating infectious diseases. Its leading drug candidate is Movantik. It is designed to treat opioid induced constipation in adults and chronic non-cancer pain. RDHL is a specialty company that focuses on inflammatory diseases of the intestines, including Crohn’s.

GILEAD SCIENCES CONDUCTING MULTIPLE DRUG TRIALS 

— Gilead Sciences (NASDAQ: GILD) is an American biopharmaceutical company with several investigational trials of compounds that can be important in the treatment of life-threatening diseases.

It is currently conducting a Phase 3 study against Crohn’s Disease with its JAK-1 inhibitor. It is conducting Phase 1 trials of its TPL2 and IRAK4 in the treatment of inflammatory bowel disease. It is also overseeing trials of candidate drugs in the treatment of Lupus and Rheumatoid Arthritis.    

Keep STAB stock on your Watch List as biopharmaceutical companies are increasing in value as clinical research studies intensify. Link to more news at https://www.staterabiopharma.com/

Disclaimers: Capital Gains Report ‘CGR’ is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by CGR is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall CGR. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by CGR., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. CGR. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, CGR., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR has been compensated one thousand five hundred dollars via wire transfer per release by Crossroads to produce and syndicate content for STAB. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

Media Contact
Company Name: Capital Gains Report
Contact Person: Mark McKelvie
Email: Send Email
City: FORT MYERS
State: FLORIDA
Country: United States
Website: http://capitalgainsreport.com/